323 related articles for article (PubMed ID: 30893889)
1. Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism-Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers?
Muthu M; Nordström A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893889
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
Amoedo ND; Obre E; Rossignol R
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics in cancer biomarker discovery: current trends and future perspectives.
Armitage EG; Barbas C
J Pharm Biomed Anal; 2014 Jan; 87():1-11. PubMed ID: 24091079
[TBL] [Abstract][Full Text] [Related]
4. Translational metabolomics in cancer research.
Snyder NW; Mesaros C; Blair IA
Biomark Med; 2015; 9(9):821-34. PubMed ID: 26329905
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics studies in gastrointestinal cancer: a systematic review.
Yu J; Zhao J; Zhang M; Guo J; Liu X; Liu L
Expert Rev Gastroenterol Hepatol; 2020 Jan; 14(1):9-25. PubMed ID: 31786962
[No Abstract] [Full Text] [Related]
6. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
8. Metabolomics: moving to the clinic.
Nordström A; Lewensohn R
J Neuroimmune Pharmacol; 2010 Mar; 5(1):4-17. PubMed ID: 19399626
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics for mitochondrial and cancer studies.
Nagrath D; Caneba C; Karedath T; Bellance N
Biochim Biophys Acta; 2011 Jun; 1807(6):650-63. PubMed ID: 21420931
[TBL] [Abstract][Full Text] [Related]
10. Review of mass spectrometry-based metabolomics in cancer research.
Liesenfeld DB; Habermann N; Owen RW; Scalbert A; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2182-201. PubMed ID: 24096148
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics of cancer.
Serkova NJ; Glunde K
Methods Mol Biol; 2009; 520():273-95. PubMed ID: 19381962
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
13. [The use of metabolomics in medicine - some examples of oncological and metabolic diseases].
Zimny D; Szatkowska M; Połubok J; Maciaszek J; Machaj M; Barg E
Pediatr Endocrinol Diabetes Metab; 2015; 20(2):55-62. PubMed ID: 26615014
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics: available results, current research projects in breast cancer, and future applications.
Claudino WM; Quattrone A; Biganzoli L; Pestrin M; Bertini I; Di Leo A
J Clin Oncol; 2007 Jul; 25(19):2840-6. PubMed ID: 17502626
[TBL] [Abstract][Full Text] [Related]
15. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics in Breast Cancer: Current Status and Perspectives.
Hart CD; Tenori L; Luchinat C; Di Leo A
Adv Exp Med Biol; 2016; 882():217-34. PubMed ID: 26987537
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.
Zhang F; Zhang Y; Zhao W; Deng K; Wang Z; Yang C; Ma L; Openkova MS; Hou Y; Li K
Oncotarget; 2017 May; 8(21):35460-35472. PubMed ID: 28389626
[TBL] [Abstract][Full Text] [Related]
18. Cancer metabolomics in basic science perspective.
Kwon H; Oh S; Jin X; An YJ; Park S
Arch Pharm Res; 2015 Mar; 38(3):372-80. PubMed ID: 25630795
[TBL] [Abstract][Full Text] [Related]
19. GC-MS based metabolomics used for the identification of cancer volatile organic compounds as biomarkers.
Lubes G; Goodarzi M
J Pharm Biomed Anal; 2018 Jan; 147():313-322. PubMed ID: 28750734
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
